Clinical trial · Observational
Risk Stratification of Nodal PTCL
Multicenter Study to Assess the Prognostic Significances of NCCN-IPI and Post-treatment PET Results in Patients With Newly Diagnosed Nodal PTCL
NCT03040206CI-TRIAL-00039951completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is to investigate the prognostic significance of enhanced International Prognostic Index (NCCN-IPI) and post-treatment PET results in patients with newly diagnosed nodal peripheral T-cell lymphoma (PTCL), and establish a risk stratification model for nodal PTCL patients.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Anaplastic Large Cell Lymphoma, ALK-negative | Anaplastic Large Cell Lymphoma, ALK-Negative | ONTOLOGY_EXACT | 0.98 |
| Angioimmunoblastic T-cell Lymphoma | Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type | ALIAS | 0.90 |
| Peripheral T-Cell Lymphoma, Not Otherwise Specified | Peripheral T-Cell Lymphoma, Not Otherwise Specified | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Nodal PTCL
- description
- 1. newly-diagnosed, pathologically-proven nodal PTCLs (PTCL, NOS; Angioimmunblastic T-cell lymphoma; anaplastic large cell lymphoma \[ALCL\], anaplastic lymphoma kinase \[ALK\]-negative) between January 1, 2005 and Jun 30, 2016 2. initially treated with curative intent 3. Standard PET or PET-CT data available at the time of diagnosis and at the end of primary treatment
Primary outcomes (1)
- measure
- progression-free survival
- timeFrame
- 5 year
- description
- Time between the date of diagnosis and any kinds of death or disease relapse/progrression
Secondary outcomes (1)
- measure
- overall survival
- timeFrame
- 5 year
- description
- Time between the date of diagnosis and any kinds of death
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients diagnosed with nodal PTCLs (PTCL, NOS; Angioimmunblastic T-cell lymphoma; anaplastic large cell lymphoma \[ALCL\], anaplastic lymphoma kinase \[ALK\]-negative) * Patients diagnosed with between January 1, 2004 and April 30, 2016 * initially treated with curative intent * Patients with standard 18F-fluorodeoxyglucose (FDG) PET or PET-CT data at the time of diagnosis and at the end of primary treatment Exclusion Criteria: * Patients diagnosed with extranodal PTCLs, including followings (extranodal NK/T-cell lymphoma, nasal type; enteropathy-associated T-cell lymphoma; hepatosplenic T-cell lymphoma; subcutaneous panniculitis-like T-cell lymphoma; EBV-positive T-cell lymphoproliferative childhood disorders, and primary cutaneous lymphomas) * Patients with ALCL-ALK+ * Patients who do not have 18F-FDG PET or PET-CT data either at diagnosis or at the end of treatment available for review
References
Publications (0)
Data not yet available
No reference posted for this study.